None of the three components are approved for human use anywhere. Here is where each stands.
BPC-157 and TB-500
Both were placed on the FDA’s “significant safety risk” (Category 2) bulk drug substances list in 2023, meaning no U.S. pharmacy may compound them.
On July 23, 2026, the FDA’s Pharmacy Compounding Advisory Committee reviewed BPC-157 (for ulcerative colitis) and TB-500 (for wound healing) and voted 8–6 to recommend adding both to the 503A bulk drug substances list. This went against the advice of FDA scientists, who argued that all substances reviewed lacked sufficient human evidence.
The votes are advisory only. Nothing was added to the list, and no pharmacy currently has a legal basis to compound either.
GHK-Cu
This is the part that gets misreported. GHK-Cu was nominated for the bulk drug substances list, but FDA nomination documents show the nomination was withdrawn on April 22, 2026, then partially restored on May 5 after one nominator clarified they only wanted to withdraw the injectable form.
As a result, GHK-Cu other than the injectable form is on Category 1, under evaluation, with advisory committee review expected by late February 2027. Injectable GHK-Cu — the only form in GLOW — is not before the committee.
Athletes
For athletes, BPC-157 and TB-500 are both on the 2026 WADA Prohibited List. BPC-157 is listed under S0 as an unapproved substance, and TB-500 under S2 by name. GHK-Cu is not on the list. A blend containing prohibited substances is a prohibited blend.
Sales
The June 2026 Wholesale Peptide warning letter and the Paradigm sentencing are the two most recent reminders that regulators and courts look at supplier marketing, not disclaimers.
Conclusion
None of GLOW’s three components are approved for human use, two are banned by WADA, and one injectable form is not under FDA review. Understanding this regulatory reality is the prerequisite for rational use.